# Sevasemten PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sevasemten

> The next catalyst for sevasemten, sponsored by Edgewise Therapeutics, Inc. (EWTX), is its primary completion, January 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | sevasemten |
| Codes | EDG-5506 |
| Sponsor | Edgewise Therapeutics, Inc. (EWTX) https://sec-api.dev/companies/ewtx/catalysts |
| Indications | becker, [becker muscular dystrophy](https://sec-api.dev/indications/becker-muscular-dystrophy), becker aged 12 years and above, [Duchenne Muscular Dystrophy](https://sec-api.dev/indications/duchenne-muscular-dystrophy) |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Jul 2022: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: Becker aged 12 years and above.
- First seen 2025-03-03, last confirmed 2025-03-03.
- SEC Form 10-K (accession 0001558370-25-002006): "In July 2022, we initiated our CANYON Phase 2 clinical trial of sevasemten, assessing the effect of sevasemten over a 12-month period on safety, PK, biomarkers of muscle damage (e.g., CK, troponins, myoglobin), and functional measures in individuals with Becker aged 12 years and above." https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm

### Nov 2022: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-03, last confirmed 2025-03-03.
- SEC Form 10-K (accession 0001558370-25-002006): "In November 2022, we initiated a Phase 2 Exercise Challenge Study (DUNE), to investigate the effect of sevasemten on muscle injury biomarkers following exercise, studied at a single site in Denmark." https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm

### April 15, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: Becker.
- First seen 2025-03-03, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001104659-26-056713): "In sevasemten, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker, on June 26, 2025, we announced encouraging topline data from our Phase 2 Duchenne trials, LYNX and FOX, and positive data from MESA, an open label extension trial that is providing continued access to sevasemten to participants with Becker who were previously enrolled in ARCH, or completed CANYON, including the GRAND CANYON pivotal cohort, or DUNE, and on March 10, 2026, we announced additional positive data from MESA." https://www.sec.gov/Archives/edgar/data/1710072/000110465926056713/ewtx-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-020112): "In sevasemten, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker, and, on June 26, 2025, we announced encouraging topline data from our Phase 2 Duchenne trials, LYNX and FOX, and positive data from MESA, an open label extension trial that is providing continued access to sevasemten to participants with Becker who were previously enrolled in ARCH, or completed CANYON, including the GRAND CANYON pivotal cohort, or DUNE." https://www.sec.gov/Archives/edgar/data/1710072/000110465926020112/ewtx-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-107427): "In sevasemten, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker, and, on June 26, 2025, we announced encouraging topline data from our Phase 2 Duchenne trials, LYNX and FOX, and positive data from MESA, an open label extension trial that is providing continued access to sevasemten to participants with Becker who were previously enrolled in ARCH, or completed CANYON, including the GRAND CANYON pivotal cohort, or DUNE." https://www.sec.gov/Archives/edgar/data/1710072/000110465925107427/ewtx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010655): "In sevasemten, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker, and, on June 26, 2025, we announced encouraging topline data from our Phase 2 Duchenne trials, LYNX and FOX, and positive data from MESA, an open label extension trial that is providing continued access to sevasemten to participants with Becker who were previously enrolled in ARCH, or completed CANYON, including the GRAND CANYON pivotal cohort, or DUNE." https://www.sec.gov/Archives/edgar/data/1710072/000155837025010655/ewtx-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006857): "For example, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker, and, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." https://www.sec.gov/Archives/edgar/data/1710072/000155837025006857/ewtx-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002006): "For example, on April 15, 2024, we announced positive two-year topline results from the ARCH open label trial of sevasemten in adults with Becker, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, and on December 16, 2024, we announced positive topline data from the Phase 2 CANYON trial of sevasemten in individuals with Becker." https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm

### December 16, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: Becker muscular dystrophy.
- First seen 2024-12-16, last confirmed 2025-05-08.
- SEC Form 8-K (accession 0001104659-24-129001): "On December 16, 2024, the Company announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy." https://www.sec.gov/Archives/edgar/data/1710072/000110465924129001/tm2431151d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-129001): "Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy." https://www.sec.gov/Archives/edgar/data/1710072/000110465924129001/tm2431151d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045896): "In December 2024, the Company announced positive topline results from CANYON, the largest interventional Becker trial to date, which evaluated 40 adults and 29 adolescents with a sevasemten treatment period of 12 months." https://www.sec.gov/Archives/edgar/data/1710072/000110465925045896/tm2513845d1_ex99-1.htm

### September 7, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Becker Muscular Dystrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05291091

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Becker Muscular Dystrophy.
- First seen 2025-06-26, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-020108): "The Company expects to report top-line data in the fourth quarter of 2026 and is continuing preparations for a potential NDA submission to the U.S. Food and Drug Administration (FDA) for sevasemten in Becker, planned for the first half of 2027." https://www.sec.gov/Archives/edgar/data/1710072/000110465926020108/tm266859d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-082902): "The GRAND CANYON pivotal cohort in Becker is fully enrolled with 175 participants and powered at greater than 98% to deliver a statistically significant difference versus placebo, with top-line data expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/tm2620181d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056783): "The Company expects to report top-line data in the fourth quarter of 2026 and is continuing preparations for a potential marketing application to seek approval as the first targeted therapy for this underserved population, planned for the first half of 2027." https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/tm2613489d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107419): "GRAND CANYON is highly powered to be able to show a statistically significant difference in NSAA versus placebo over 18 months and the Company expects to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465925107419/tm2529979d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-074987): "GRAND CANYON is highly powered to be able to show a statistically significant difference in NSAA versus placebo over 18 months and is on track for topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/tm2522645d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-063028): "GRAND CANYON is highly powered to show a statistically significant difference in NSAA versus placebo over 18 months and is on track for topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1710072/000110465925063028/tm2519221d1_8k.htm
- ClinicalTrials.gov: "NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05291091

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Duchenne Muscular Dystrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05540860 (A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05540860

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Duchenne Muscular Dystrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05540860 (A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05540860

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Duchenne Muscular Dystrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06100887 (Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06100887

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Duchenne Muscular Dystrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06100887 (Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Edgewise Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06100887

## Same indication

- [Translarna™ (ataluren)](https://sec-api.dev/pdufa/ataluren) (PTCT)
- [ELEVIDYS (delandistrogene moxeparvovec)](https://sec-api.dev/pdufa/delandistrogene-moxeparvovec) (SRPT)
- [Fordadistrogene movaparvovec](https://sec-api.dev/pdufa/fordadistrogene-movaparvovec) (PFE)
- [Pgn-edo51](https://sec-api.dev/pdufa/pgn-edo51) (PEPG)
- [RGX-202](https://sec-api.dev/pdufa/rgx-202) (RGNX)
- [SAT-3247](https://sec-api.dev/pdufa/sat-3247) (MSLE)
- [Wve-n531](https://sec-api.dev/pdufa/wve-n531) (WVE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sevasemten.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sevasemten PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sevasemten

```bibtex
@misc{secapidev_pdufa_sevasemten_20261116,
  title        = {Sevasemten PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sevasemten}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sevasemten_20261116","title":"Sevasemten PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sevasemten","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
